PL2493922T3 - Sposób wytwarzania glikozylowanych immunoglobulin - Google Patents

Sposób wytwarzania glikozylowanych immunoglobulin

Info

Publication number
PL2493922T3
PL2493922T3 PL10771093T PL10771093T PL2493922T3 PL 2493922 T3 PL2493922 T3 PL 2493922T3 PL 10771093 T PL10771093 T PL 10771093T PL 10771093 T PL10771093 T PL 10771093T PL 2493922 T3 PL2493922 T3 PL 2493922T3
Authority
PL
Poland
Prior art keywords
glycosyled
immunoglobulins
make
make glycosyled
glycosyled immunoglobulins
Prior art date
Application number
PL10771093T
Other languages
English (en)
Inventor
Reinhard Franze
Chikashi Hirashima
Thomas Link
Yoshinori Takagi
Shinya Takuma
Yuriko Tsuda
Original Assignee
F.Hoffmann-La Roche Ag
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42060615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2493922(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F.Hoffmann-La Roche Ag, Chugai Seiyaku Kabushiki Kaisha filed Critical F.Hoffmann-La Roche Ag
Publication of PL2493922T3 publication Critical patent/PL2493922T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PL10771093T 2009-10-26 2010-10-25 Sposób wytwarzania glikozylowanych immunoglobulin PL2493922T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09013455 2009-10-26
EP10771093.1A EP2493922B1 (en) 2009-10-26 2010-10-25 Method for the production of a glycosylated immunoglobulin

Publications (1)

Publication Number Publication Date
PL2493922T3 true PL2493922T3 (pl) 2017-07-31

Family

ID=42060615

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17155939.6T PL3202785T3 (pl) 2009-10-26 2010-10-25 Sposób wytwarzania glikozylowanej immunoglobuliny
PL10771093T PL2493922T3 (pl) 2009-10-26 2010-10-25 Sposób wytwarzania glikozylowanych immunoglobulin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17155939.6T PL3202785T3 (pl) 2009-10-26 2010-10-25 Sposób wytwarzania glikozylowanej immunoglobuliny

Country Status (19)

Country Link
US (8) US20110117087A1 (pl)
EP (3) EP2493922B1 (pl)
JP (7) JP5711751B2 (pl)
KR (8) KR101436219B1 (pl)
CN (2) CN104928336B (pl)
AU (1) AU2010311567B2 (pl)
BR (2) BR122022001178B1 (pl)
CA (1) CA2773522C (pl)
DK (1) DK2493922T3 (pl)
ES (2) ES2981683T3 (pl)
HR (1) HRP20240920T1 (pl)
HU (2) HUE067718T2 (pl)
IL (3) IL263849B1 (pl)
MX (2) MX2012004682A (pl)
PL (2) PL3202785T3 (pl)
SG (2) SG10201913329XA (pl)
SI (2) SI2493922T1 (pl)
TW (8) TW201540837A (pl)
WO (1) WO2011051231A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN104928336B (zh) * 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
EP2787007A3 (en) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
EP2765192A4 (en) * 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd ANTIGENBINDING MOLECULE FOR PREPARING A SPACE BETWEEN A PLASMA AND AN ANTIGEN WITH A SACCHARIDE CHAIN RECEPTOR BINDING DOMAIN
EP2970916B1 (en) 2013-03-13 2021-04-14 Merck Sharp & Dohme Corp. Adapted lepidopteran insect cells for the production of recombinant proteins
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
SG10202113019XA (en) * 2014-06-04 2021-12-30 Amgen Inc Methods for harvesting mammalian cell cultures
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TW201723174A (zh) * 2015-09-03 2017-07-01 持田製藥股份有限公司 重組蛋白質的製造方法
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
EP3596175A4 (en) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation NANOPARTICLES FOR THE ADMINISTRATION OF CHEMOPREVENTIVE AGENTS
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20230323422A1 (en) * 2020-08-14 2023-10-12 Bristol-Myers Squibb Company Method of making protein
JPWO2023190300A1 (pl) * 2022-03-28 2023-10-05
KR102682350B1 (ko) 2024-03-15 2024-07-05 주식회사 가미코스메틱 저자극성 친환경 샴푸 조성물 및 이의 제조 방법

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926723A (en) 1974-08-08 1975-12-16 Massachusetts Inst Technology Method of controllably releasing glucose to a cell culture medium
US4657863A (en) * 1982-07-02 1987-04-14 Celanese Corporation Stabilization of a mutant microorganism population
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
JPS62258252A (ja) 1986-04-30 1987-11-10 Koyo Seiko Co Ltd ベルト用オ−トテンシヨナ
JPH066054B2 (ja) 1987-10-15 1994-01-26 帝人株式会社 動物細胞の培養方法
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
CA1312030C (en) 1987-11-18 1992-12-29 Brian Maiorella Method to increase antibody titer
US6238891B1 (en) 1987-11-18 2001-05-29 Cetus Oncology Corporation Method of increasing product expression through solute stress
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
KR0132666B1 (en) 1989-03-14 1998-04-14 Hitachi Kk Method for controlling cultivation conditions for animal cells
ATE144713T1 (de) 1989-07-20 1996-11-15 Tadamitsu Kishimoto Antikörper gegen menschlichen interleukin-6- rezeptor
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
CA2078546A1 (en) 1990-04-03 1991-10-04 Phillip W. Berman Methods and compositions for vaccination against hiv
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
DE4037325A1 (de) 1990-11-23 1992-05-27 Karl Mueller U Co Kg Verfahren zur erzeugung von zellmasse und/oder fermentierungsprodukten unter sterilen bedingungen sowie vorrichtung zur durchfuehrung des verfahrens
JPH05227970A (ja) 1992-02-19 1993-09-07 Chugai Pharmaceut Co Ltd ヒトインターロイキン−６受容体に対する再構成ヒト抗体
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US5821121A (en) 1991-06-24 1998-10-13 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
ATE215605T1 (de) 1991-06-24 2002-04-15 Pacific Biomedical Res Inc In langzeitkultur gehaltene hormon-absondernde pankreatische zellen
US5650508A (en) 1991-12-27 1997-07-22 Georgia Tech Research Corporation Peptide ketoamides
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
WO1993022448A1 (en) 1992-05-01 1993-11-11 Teijin Limited Fed batch culture method for protein secreting cells
EP0567738A3 (en) 1992-05-01 1995-09-06 American Cyanamid Co Controlling perfusion rates in continuous bioreactor culture of animal cells
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JPH06292592A (ja) * 1993-02-09 1994-10-21 Snow Brand Milk Prod Co Ltd 糖蛋白質の生産方法
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
USH1532H (en) 1993-11-03 1996-05-07 Genetics Institute, Inc. Adaption of mammalian cell lines to high cell densities
JP3442784B2 (ja) 1993-11-23 2003-09-02 ジェネンテク，インコーポレイテッド キナーゼ受容体活性化検定法
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
EP0756003B1 (en) 1994-02-18 1999-03-24 Teijin Limited Method of culturing animal cells
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
CA2190101A1 (en) 1994-05-13 1995-11-23 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
JP3630453B2 (ja) 1994-09-30 2005-03-16 中外製薬株式会社 Ｉｌ−６レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤
PL182089B1 (en) 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
AU704723B2 (en) 1994-12-29 1999-04-29 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
DK0811384T3 (da) 1995-02-13 2006-10-09 Chugai Pharmaceutical Co Ltd Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof
GB9506249D0 (en) * 1995-03-27 1995-05-17 Karobio Ab Media for insect cell cultures
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP3596108B2 (ja) 1995-08-30 2004-12-02 株式会社デンソー 車両用空調装置
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
PT923941E (pt) 1996-06-27 2006-09-29 Chugai Pharmaceutical Co Ltd Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
JP3707583B2 (ja) 1997-06-06 2005-10-19 株式会社ブリヂストン 金属線用ガイド
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
PT1074268E (pt) 1998-03-17 2008-02-28 Chugai Pharmaceutical Co Ltd Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6537782B1 (en) 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
ES2276525T3 (es) * 1998-08-24 2007-06-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo.
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6338964B1 (en) 1999-05-07 2002-01-15 Bayer Corporation Process and medium for mammalian cell culture under low dissolved carbon dioxide concentration
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US6284453B1 (en) 1999-09-29 2001-09-04 Steven Anthony Siano Method for controlling fermentation growth and metabolism
JP2001101882A (ja) 1999-09-29 2001-04-13 Sony Corp 不揮発性半導体記憶装置
AU5901501A (en) 1999-10-19 2001-10-23 Nicholas R. Abu-Absi Measurement of nutrient uptake in cells and methods based thereon
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
WO2001092555A1 (en) 2000-05-30 2001-12-06 Lactascan Aps Method for producing lactic acid
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
EP1298217A4 (en) * 2000-07-05 2004-09-08 Mitsubishi Pharma Corp Process for the production of a glycoprotein
JP4812228B2 (ja) 2000-08-10 2011-11-09 中外製薬株式会社 抗体含有溶液の凝集物生成または白濁抑制方法
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002030954A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Method of purifying antibody
US8703126B2 (en) * 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
PT1356073E (pt) 2000-10-20 2010-02-15 Bioneer As Método de fermentação aperfeiçoado para a produção de produtos genéticos heterólogos em bactérias do ácido láctico
JP4261907B2 (ja) 2000-10-20 2009-05-13 中外製薬株式会社 低分子化アゴニスト抗体
WO2002034292A1 (fr) 2000-10-25 2002-05-02 Chugai Seiyaku Kabushiki Kaisha Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
WO2002036165A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
WO2002036164A1 (en) * 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
CA2426100A1 (en) 2000-11-03 2002-05-23 Genentech, Inc. Metabolic rate shifts in fermentations expressing recombinant proteins
CA2430270A1 (en) 2000-11-22 2002-05-30 Cargill Dow Polymers, Llc Methods and materials for the synthesis of organic products
PA8535501A1 (es) 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
CZ20031886A3 (cs) 2001-01-19 2003-10-15 Basf Aktiengesellschaft Způsob přípravy pantothenátu ve vyšším výtěžku a mikroorganizmy používané při tomto způsobu
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
WO2002076578A1 (en) 2001-03-27 2002-10-03 Smithkline Beecham Corporation Control of glycoforms in igg
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1382964A4 (en) 2001-04-17 2009-06-10 Chugai Pharmaceutical Co Ltd METHOD FOR TENSID QUANTIFICATION
KR20020088848A (ko) 2001-05-21 2002-11-29 (주)코아바이오텍 세포배양관 및 이를 이용한 대량 세포배양기
WO2002101019A2 (en) 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
CA2455722A1 (en) 2001-07-23 2003-02-06 Zymogenetics, Inc. Fermentation medium and method
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CA2473039C (fr) 2002-01-18 2014-09-23 Pierre Fabre Medicament Nouveaux anticorps anti-igf-ir et leurs applications
WO2003066816A2 (en) 2002-02-08 2003-08-14 Genencor International, Inc. Methods for producing end-products from carbon substrates
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
JP3958089B2 (ja) 2002-03-26 2007-08-15 有限会社新世紀発酵研究所 嫌気性菌の連続培養法
JP3822137B2 (ja) 2002-05-20 2006-09-13 中外製薬株式会社 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法
NZ536475A (en) 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
US8142810B2 (en) 2002-05-30 2012-03-27 The Procter & Gamble Company Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CA2491145A1 (en) 2002-07-03 2004-01-15 Basf Aktiengesellschaft Microorganisms and processes for enhanced production of pantothenate
US20060099692A1 (en) 2002-07-03 2006-05-11 Yocum R R Microorganisms and processes for enhanced production of pantothenate
CN1470632A (zh) 2002-07-25 2004-01-28 谢良志 一种动物细胞的优化流加悬浮培养方法
ES2626268T3 (es) 2002-09-11 2017-07-24 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
AU2003291254A1 (en) 2002-11-05 2004-06-07 Mount Sinai School Of Medicine Of New York University ; Ptpn11 (shp-2) mutations and cancer
DE10255508A1 (de) 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
CZ308720B6 (cs) 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
CA2514231A1 (en) 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies
CA2516945A1 (en) 2003-02-24 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for spinal cord injury comprising interleukin-6 antagonist
MXPA05009837A (es) 2003-03-14 2005-12-05 Pharmacia Corp Anticuerpos para el receptor del factor de crecimiento tipo insulina-i, para el tratamiento de canceres.
ES2383014T3 (es) 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US7429491B2 (en) * 2003-05-15 2008-09-30 Wyeth Restricted glucose feed for animal cell culture
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
DK1656391T3 (da) 2003-08-13 2011-01-03 Pfizer Prod Inc Modificerede humane IGF-1R antistoffer
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
RU2554942C2 (ru) 2003-10-17 2015-07-10 Тугаи Сейяку Кабусики Кайся Терапевтический агент для мезотелиомы
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
ES2368741T3 (es) 2004-02-25 2011-11-21 Dana-Farber Cancer Institute, Inc. Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
AR048335A1 (es) * 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
WO2005115453A2 (en) 2004-04-16 2005-12-08 Genentech, Inc. Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
RU2342159C2 (ru) 2004-07-16 2008-12-27 Пфайзер Продактс Инк. Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US7432359B2 (en) 2004-09-06 2008-10-07 Kirin Pharma Kabushiki Kaisha Anti-A33 antibody
JP4818936B2 (ja) 2005-01-05 2011-11-16 中外製薬株式会社 細胞の培養方法およびその利用
AU2006300234B2 (en) * 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
ES2417147T3 (es) 2005-10-21 2013-08-06 Revo Biologics, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
CN101371140B (zh) 2006-03-09 2013-11-13 弗·哈夫曼-拉罗切有限公司 抗药物抗体的测定
US7612178B2 (en) 2006-03-28 2009-11-03 Biogen Idec Ma Inc Anti-IGF-1R antibodies and uses thereof
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
NZ587107A (en) * 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008016134A1 (fr) 2006-08-04 2008-02-07 Norihiro Nishimoto PROCÉDÉ POUR PRÉDIRE LE PRONOSTIC DES PATIENTS ATTEINTS DE POLYARTHRITE rhumatoïde
WO2008036600A2 (en) 2006-09-18 2008-03-27 Genentech, Inc. Methods of protein production
JP4355743B2 (ja) * 2006-12-04 2009-11-04 株式会社神戸製鋼所 Ｃｕ合金配線膜とそのＣｕ合金配線膜を用いたフラットパネルディスプレイ用ＴＦＴ素子、及びそのＣｕ合金配線膜を作製するためのＣｕ合金スパッタリングターゲット
JP2010095445A (ja) 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
CN101754772B (zh) 2007-05-21 2015-08-19 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
EP3246045B1 (en) 2007-07-26 2025-09-03 Osaka University Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
AU2008308163B2 (en) 2007-10-02 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
JP2009092508A (ja) 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
BRPI0818674B1 (pt) 2007-10-15 2023-01-17 Chugai Seiyaku Kabushiki Kaisha Métodos para produção de um anticorpo inteiro ou de um fragmento do mesmo e para preparação de fármacos, bem como vetor recombinante
GB2453939A (en) 2007-10-22 2009-04-29 Ubidyne Inc Clockless analogue band-pass delta-sigma modulator
US8227195B2 (en) * 2007-12-15 2012-07-24 Hoffman-La Roche Inc. Distinguishing assay
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2271669A1 (en) 2008-03-11 2011-01-12 Genentech, Inc. Antibodies with enhanced adcc function
DE102008013899A1 (de) * 2008-03-12 2009-09-17 F. Hoffmann-La Roche Ag Verfahren zur Herstellung rekombinanter Proteine bei konstantem Gehalt von pCO2 im Medium
TWI528973B (zh) * 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
TW201600110A (zh) 2009-07-31 2016-01-01 Shin Maeda 癌之轉移抑制劑
WO2011019622A1 (en) * 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
CN104928336B (zh) * 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2011128096A1 (en) * 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
EP2578233B1 (en) 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
CA2801107A1 (en) * 2010-06-07 2011-12-15 F. Hoffman-La Roche Ag Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
MX342235B (es) 2010-11-05 2016-09-21 Hoffmann La Roche Metodo optimizado para captura de anticuerpo por cromatografia de modo mixto.
EP2787007A3 (en) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
KR101993488B1 (ko) 2011-09-01 2019-06-26 추가이 세이야쿠 가부시키가이샤 한외여과에 의해 고도로 농축된 항체를 포함하는 조성물의 제조 방법
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
TWI873632B (zh) 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
AR104050A1 (es) 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados

Also Published As

Publication number Publication date
JP5982024B2 (ja) 2016-08-31
SI2493922T1 (sl) 2017-06-30
TW201125976A (en) 2011-08-01
IL326973A (en) 2026-05-01
EP4406615A3 (en) 2024-12-11
US11377678B2 (en) 2022-07-05
TW201540837A (zh) 2015-11-01
SG10201510640QA (en) 2016-01-28
IL218997A0 (en) 2012-06-28
TWI675104B (zh) 2019-10-21
TW202444753A (zh) 2024-11-16
KR101436219B1 (ko) 2014-09-01
TW202116354A (zh) 2021-05-01
EP2493922A1 (en) 2012-09-05
US20220380827A1 (en) 2022-12-01
DK2493922T3 (en) 2017-04-24
HUE067718T2 (hu) 2024-11-28
JP5711751B2 (ja) 2015-05-07
TW201619392A (zh) 2016-06-01
BR112012009828B1 (pt) 2022-05-03
TWI724448B (zh) 2021-04-11
KR20210024685A (ko) 2021-03-05
IL263849B1 (en) 2026-04-01
PL3202785T3 (pl) 2024-08-12
HRP20240920T1 (hr) 2024-10-11
EP4406615A2 (en) 2024-07-31
SG10201913329XA (en) 2020-02-27
JP2020058371A (ja) 2020-04-16
CA2773522A1 (en) 2011-05-05
JP2024125388A (ja) 2024-09-18
TW202330028A (zh) 2023-08-01
MX2019000097A (es) 2023-01-05
ES2981683T3 (es) 2024-10-10
KR101860175B1 (ko) 2018-05-21
BR112012009828A2 (pt) 2020-08-18
SI3202785T1 (sl) 2024-08-30
KR101961254B1 (ko) 2019-03-22
BR112012009828B8 (pt) 2022-10-25
CN102596995A (zh) 2012-07-18
CA2773522C (en) 2023-04-18
JP2019001796A (ja) 2019-01-10
TW201938197A (zh) 2019-10-01
KR20190060877A (ko) 2019-06-03
KR102223417B1 (ko) 2021-03-05
EP3202785A1 (en) 2017-08-09
BR112012009828A8 (pt) 2020-09-24
JP6385988B2 (ja) 2018-09-05
AU2010311567B2 (en) 2015-03-26
JP2015128436A (ja) 2015-07-16
US20110117087A1 (en) 2011-05-19
KR20190031342A (ko) 2019-03-25
AU2010311567A1 (en) 2012-04-19
KR20120080640A (ko) 2012-07-17
CN104928336A (zh) 2015-09-23
JP2013507979A (ja) 2013-03-07
US20160186228A1 (en) 2016-06-30
US11136610B2 (en) 2021-10-05
US20220282298A1 (en) 2022-09-08
CN104928336B (zh) 2020-05-08
JP7083802B2 (ja) 2022-06-13
US20210246478A1 (en) 2021-08-12
TWI795722B (zh) 2023-03-11
WO2011051231A1 (en) 2011-05-05
BR122022001178B1 (pt) 2022-10-04
CN102596995B (zh) 2015-08-12
HUE033758T2 (en) 2017-12-28
KR20140091070A (ko) 2014-07-18
KR20180014847A (ko) 2018-02-09
KR20170110167A (ko) 2017-10-10
TWI832492B (zh) 2024-02-11
KR20160084500A (ko) 2016-07-13
TWI670375B (zh) 2019-09-01
MX2012004682A (es) 2012-09-07
TW201812013A (zh) 2018-04-01
US10501769B2 (en) 2019-12-10
ES2622366T3 (es) 2017-07-06
KR101985153B1 (ko) 2019-05-31
US20210381020A1 (en) 2021-12-09
KR102319842B1 (ko) 2021-11-01
US20200080125A1 (en) 2020-03-12
US11021728B2 (en) 2021-06-01
IL263849A (en) 2019-01-31
EP3202785B1 (en) 2024-05-08
US20200181669A1 (en) 2020-06-11
EP2493922B1 (en) 2017-02-15
JP2017019799A (ja) 2017-01-26
HK1210224A1 (zh) 2016-04-15
TWI534264B (zh) 2016-05-21
KR102071834B1 (ko) 2020-01-30
HK1171237A1 (en) 2013-03-22
JP2022116264A (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
DK2521736T3 (da) Humaniserede antistoffer
BR112012020964A2 (pt) método de produção de imunoglobulina
PT2406284T (pt) Anticorpos anti-bcma
LT2975051T (lt) Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
BR112012030311A2 (pt) anticorpo
PT2530091T (pt) Anticorpo anti-dll3
CR20130228A (es) Anticuerpos neutralizadores anti-ccl20
PT2516457T (pt) Ratinhos fcyr humanizados
EP2629796A4 (en) ANTIBODY
EP2624323A4 (en) Photoelectric conversion element
SMT201700083B (it) Anticorpi monoclonali
EP2400820A4 (en) DEVICE PROVIDING LOADS
EP2563492A4 (en) Site drainer
CO6791565A2 (es) Anticuerpos anti-notch1
FR2958258B1 (fr) Tricycle
EP2772945A4 (en) PHOTOELECTRIC CONVERSION ELEMENT
BR112014011011A2 (pt) seções de estrutura de poços
FI20145657L (fi) Vesitiivis kansiosa
BRPI0923541A2 (pt) purificação de imunoglobulina
BR112013015829A2 (pt) variantes de endoglucanase
EP2548182A4 (en) SALE DEVICE
HUE043576T2 (hu) Antitestek notum pektinacetilészterázhoz
FR2961784B1 (fr) Bicyclette pliable
EP2672522A4 (en) PHOTOELECTRIC CONVERSION ELEMENT
BR112013010784A2 (pt) aquecedor de combustão